Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 1/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381400 | 1.00 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2ALK | |
| SCHEMBL29361383 | 1.00 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2ALK | |
| SCHEMBL14344430 | 0.89 | TGFBR1 (0.80) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL13799240 | 0.87 | TGFBR1 (0.78) | TGFBR1PRKD3PRKD1PRKD2ALK | |
| SCHEMBL24744356 | 0.87 | TGFBR1 (0.77) | TGFBR1PRKD3PRKD1PRKD2ALK | |
| SCHEMBL2128085 | 0.87 | TGFBR1 (0.77) | TGFBR1PRKD3PRKD1PRKD2ALK | |
| SCHEMBL14344351 | 0.85 | TGFBR1 (0.74) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL5551403 | 0.85 | TGFBR1 (0.74) | TGFBR1PRKD3PRKD1PRKD2ALK | |
| SCHEMBL14344357 | 0.84 | TGFBR1 (0.72) | TGFBR1PRKD3PRKD1PRKD2LMNA | |
| SCHEMBL2394051 | 0.84 | TGFBR1 (0.72) | TGFBR1PRKD3PRKD1PRKD2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-3047017-B1 | METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS | UNIV CALIFORNIA (US) | 2025-09-10 | — | — | EP | claimed |
| US-12371664-B2 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby | CHA BIOTECH CO., LTD. (KR) | 2025-07-29 | — | — | US | claimed |
| WO-2024262844-A1 | NANOPARTICLES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | 한양대학교 산학협력단 | 2024-12-26 | — | — | WO | claimed |
| US-20230364153-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | Research & Business Foundation Sungkyunkwan University (KR) | 2023-11-16 | — | — | US | claimed |
| US-20230310402-A1 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-10-05 | — | — | US | claimed |
| US-11730722-B2 | Corneal endothelium ECM therapeutic medicaments | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-08-22 | — | — | US | claimed |
| WO-2023060322-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | MURDOCH CHILDREN'S RESEARCH INSTITUTE (AU) | 2023-04-20 | — | — | WO | claimed |
| US-20220296580-A1 | THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2022-09-22 | — | — | US | claimed |
| US-11382904-B2 | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2022-07-12 | — | — | US | claimed |
| WO-2015087231-A1 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS | PFIZER LIMITED (GB) | 2015-06-18 | — | — | WO | claimed |
| US-20150159134-A1 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS | PFIZER LIMITED (GB) | 2015-06-11 | — | — | US | claimed |
| WO-2015061568-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-04-30 | — | — | WO | claimed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | claimed |
| US-20150044178-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2015-02-12 | — | — | US | claimed |
| US-20140348889-A1 | Compositions and Methods for Treating and Preventing Neointimal Stenosis | YALE UNIVERSITY (US) | 2014-11-27 | — | — | US | claimed |
| US-8883502-B2 | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-11 | — | — | US | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | claimed |
| WO-2012167261-A2 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEOINTIMAL STENOSIS | YALE UNIVERSITY (US) | 2012-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150159134-A1 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS | ALDH1A2, ALDH1A3, EYA3 | TGFBR1 4643/4885PRKD3 2182/4885PRKD1 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.